Arca
Skip to content

IL3RA: Interleukin-3 receptor subunit alpha

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells.

  • Drugs that act on it: 5
  • With a US drug page: 2
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
Pivekimab sunirineApprovedInterleukin-3 receptor subunit alpha binding agentBinding agent—
TagraxofuspApprovedInterleukin-3 receptor subunit alpha binding agentBinding agentBoxed warning
CSL-360—Interleukin-3 receptor subunit alpha inhibitorInhibitor—
Flotetuzumab—Interleukin-3 receptor subunit alpha binding agentBinding agent—
Talacotuzumab—Interleukin-3 receptor subunit alpha binding agentBinding agent—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
CD4+/CD56+ hematodermic neoplasm
0.42
Acute myeloid leukemia by FAB classification
0.40
Neoplasm
0.40
Neurodegenerative disease
0.24
Triple-negative breast carcinoma
0.09
Hematopoietic and lymphoid cell neoplasm
0.09
Acute leukemia
0.08

Drugs and mechanisms are from ChEMBL CHEMBL3712987 (CC BY-SA 3.0). Gene name, function (UniProt P26951, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.